Zydus receives EIR for the formulation manufacturing facility at SEZ 2, Ahmedabad

Zydus Lifesciences Ltd has received the EIR report from the USFDA for the inspection conducted at the formulation manufacturing facility named 'SEZ 2' located at Pharmez, Ahmedabad from 3 rd to 7th July, 2023. This was a Pre-Approval Inspection (PAI) and had concluded with NIL observations.

Shares of Zydus Lifesciences Limited was last trading in BSE at Rs. 643.45 as compared to the previous close of Rs. 645.65. The total number of shares traded during the day was 58211 in over 2659 trades.

The stock hit an intraday high of Rs. 653.55 and intraday low of 641.00. The net turnover during the day was Rs. 37748350.00.

Source : Equity Bulls

Keywords

ZydusLifesciences INE010B01027 EIR USFDA FormulationFacility SEZ2